title: Laser in situ keratomileusis for residual refractive errors after apodized diffractive multifocal intraocular lens implantation.
abstract: OBJECTIVE
  To evaluate the visual and refractive outcomes of laser in situ keratomileusis (LASIK) to correct residual refractive error after apodized diffractive multifocal intraocular lens (IOL) implantation.
  
  
  METHODS
  University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  
  
  METHODS
  This retrospective study reviewed eyes of consecutive patients who had LASIK using the IntraLase FS60 femtosecond laser and Visx Star S4 excimer laser to correct residual refractive error after AcrySof ReSTOR IOL implantation.
  
  
  RESULTS
  The review comprised 85 eyes of 59 patients. Thirty-six eyes (42.3%) had myopic correction, 35 (41.2%) had mixed astigmatic correction, and 14 (16.5%) had hyperopic correction; 45 eyes (52.9%) also had neodymium:YAG (Nd:YAG) capsulotomy. Six months after LASIK, 91.8% of eyes had an uncorrected distance visual acuity (UCVA) of 20/25 or better, 92.9% had an uncorrected near visual acuity (UCNVA) of J1 or better, and 85.9% had 20/25 or better UCVA concurrent with J1 or better UCNVA. No eye lost more than 1 line of best spectacle-corrected visual acuity; 2 eyes (2.4%) lost 1 line. Ninety-nine percent of eyes were within +/-1.00 diopter (D) of emmetropia, and 98% of eyes were within +/-1.00 D cylinder. There was no significant difference in postoperative UCVA or UCNVA between the 3 refraction groups (P >.05) or between eyes that had Nd:YAG capsulotomy and those that did not (P >.05).
  
  
  CONCLUSIONS
  Laser in situ keratomileusis for residual ametropia after apodized diffractive multifocal IOL implantation was predictable, effective, and safe.
authors.affiliation: Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9057, USA.
authors.forename: Orkun
authors.initials: O
authors.lastname: Muftuoglu
authors.forename: Pawan
authors.initials: P
authors.lastname: Prasher
authors.forename: Claire
authors.initials: C
authors.lastname: Chu
authors.forename: V Vinod
authors.initials: VV
authors.lastname: Mootha
authors.forename: Steven M
authors.initials: SM
authors.lastname: Verity
authors.forename: H Dwight
authors.initials: HD
authors.lastname: Cavanagh
authors.forename: R Wayne
authors.initials: RW
authors.lastname: Bowman
authors.forename: James P
authors.initials: JP
authors.lastname: McCulley
mesh_terms: D000328:Adult; D000368:Aged; D003315:Cornea / Q000503:physiopathology / Q000601:surgery*; D005260:Female; D006801:Humans; D006956:Hyperopia / Q000209:etiology / Q000601:surgery*; D020731:Keratomileusis, Laser In Situ; D054018:Lasers, Excimer / Q000627:therapeutic use*; D053844:Lasers, Solid-State / Q000627:therapeutic use; D007903:Lens Capsule, Crystalline / Q000601:surgery; D019654:Lens Implantation, Intraocular / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000209:etiology / Q000601:surgery*; D018918:Phacoemulsification; D019591:Pseudophakia / Q000503:physiopathology; D012086:Reoperation; D012189:Retrospective Studies; D014792:Visual Acuity / Q000502:physiology